A5015394039- PI3K/AKT/mTOR signaling in cancer
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Liver Disease Diagnosis and Treatment
- Liver physiology and pathology
- T-cell and B-cell Immunology
- Ferroptosis and cancer prognosis
- MicroRNA in disease regulation
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Mechanisms and Therapy
- RNA regulation and disease
- Computational Drug Discovery Methods
- Synthesis and biological activity
- Cancer, Hypoxia, and Metabolism
- Protein Tyrosine Phosphatases
- Hepatitis B Virus Studies
- Pharmacogenetics and Drug Metabolism
- Protein Kinase Regulation and GTPase Signaling
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Single-cell and spatial transcriptomics
- Histone Deacetylase Inhibitors Research
Oncode Institute
2019-2025
The Netherlands Cancer Institute
2019-2025
Abstract Myeloid cells are abundant and plastic immune cell subsets in the liver, to which pro-tumorigenic, inflammatory immunosuppressive roles have been assigned course of tumorigenesis. Yet several aspects underlying their dynamic alterations hepatocellular carcinoma (HCC) progression remain elusive, including impact distinct genetic mutations shaping a cancer-permissive tumor microenvironment (TME). Here, newly generated, clinically-relevant somatic female HCC mouse models, we identify...
Inflammatory cytokines are pivotal to immune responses. Upon cytokine exposure, cells enter an "alert state" that enhances their visibility the system. Here, we identified alert-state subpopulation of ribosomes defined by presence P-stalk. We show P-stalk (PSRs) formed in response linked tumor immunity, and this is at least partially mediated phosphorylation. PSRs involved preferential translation mRNAs vital for via more efficient transmembrane domains receptor molecules cytokine-mediated...
Liver cancer is the fourth most common cause of cancer-related death worldwide, with hepatocellular carcinoma (HCC) being main primary malignancy affecting liver. Unfortunately, there are still limited therapeutic options for HCC, and even latest advances have only increased overall survival modestly. Thus, new treatment strategies rational drug combinations urgently needed. Reactivation receptor tyrosine kinases (RTK) has been described as a mechanism intrinsic resistance to targeted...
Quantitative differences in signal transduction are to date an understudied feature of tumour heterogeneity. The MAPK Erk pathway, which is activated a large proportion human tumours, prototypic example distinct cell fates being driven by intensity. We have used primary hepatocyte precursors transformed with different dosages oncogenic form Ras model subclonal variations signalling. Orthotopic allografts Ras-transformed cells immunocompromised mice gave rise fast-growing aggressive both at...
Abstract The rising incidence and increasing mortality of hepatocellular carcinoma (HCC), combined with its high tumor heterogeneity, lack druggable targets, tendency to develop resistance chemotherapeutics, make the development better models for this cancer an urgent challenge. To mimic diversity within HCC genetic landscape, versatile somatic murine have recently been developed using hydrodynamic tail vein injection (HDTVi) system. These represent novel in vivo tools interrogate phenotype...
Abstract Myeloid cells are abundant and plastic immune cell subsets in the liver, to which pro-tumorigenic, inflammatory immunosuppressive roles have been assigned course of tumorigenesis. Yet several aspects underlying their dynamic alterations hepatocellular carcinoma (HCC) progression remain elusive, including impact distinct genetic mutations shaping a cancer-permissive tumor microenvironment (TME). Here, we generated somatic HCC mouse models bearing clinically-relevant oncogenic driver...
Abstract Quantitative differences in signal transduction are to date an understudied feature of tumour heterogeneity. The MAPK Erk pathway, which is activated a large proportion human tumours, prototypic example distinct cell fates being driven by intensity. We have used primary hepatocyte precursors transformed with different dosages oncogenic form Ras model subclonal variations signalling. Orthotopic allografts Ras-transformed cells immunocompromised mice gave rise fast-growing aggressive...